{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:42:24Z","timestamp":1792676544265,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:14:55Z","timestamp":1775823295000},"page":"478-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remyelination and neuroprotection translational trials: Lessons from optic neuritis"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-1531","authenticated-orcid":false,"given":"C.","family":"Louapre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Beigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meyniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Touitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neurol.2026.03.009_bib0310","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: from basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0315","doi-asserted-by":"crossref","first-page":"9837","DOI":"10.1038\/s41467-024-54003-9","article-title":"Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair","volume":"15","author":"Hur\u00e9","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2026.03.009_bib0320","doi-asserted-by":"crossref","first-page":"eads0633","DOI":"10.1126\/scitranslmed.ads0633","article-title":"In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis","volume":"18","author":"Gacem","year":"2026","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2026.03.009_bib0325","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaneurol.2019.3283","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis","volume":"77","author":"Andorr\u00e0","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0335","doi-asserted-by":"crossref","first-page":"e2468","DOI":"10.1212\/WNL.0000000000009504","article-title":"Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS","volume":"94","author":"Davion","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0340","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0345","doi-asserted-by":"crossref","first-page":"e214515","DOI":"10.1212\/WNL.0000000000214515","article-title":"Iron-rim lesions in the optic chiasm in multiple sclerosis: a neuropathologic case series","volume":"106","author":"Lockhart","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0350","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/brain\/awq080","article-title":"Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration","volume":"133","author":"Green","year":"2010","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bpa.12193","article-title":"Oligodendrocyte lineage cells in chronic demyelination of multiple sclerosis optic nerve","volume":"25","author":"Jennings","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fneur.2011.00050","article-title":"Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis","volume":"2","author":"Quinn","year":"2011","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0365","doi-asserted-by":"crossref","first-page":"24048","DOI":"10.1038\/s41598-024-73792-z","article-title":"Demyelination and neurodegeneration early in experimental autoimmune encephalomyelitis contribute to functional deficits in the anterior visual pathway","volume":"14","author":"Sekyi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2026.03.009_bib0370","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/1352458506070629","article-title":"Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis","volume":"12","author":"Shindler","year":"2006","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.03.009_bib0375","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature11314","article-title":"Oligodendroglia metabolically support axons and contribute to neurodegeneration","volume":"487","author":"Lee","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2026.03.009_bib0380","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.neuro.30.051606.094309","article-title":"Axon-glial signaling and the glial support of axon function","volume":"31","author":"Nave","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.neurol.2026.03.009_bib0385","first-page":"262847","article-title":"Mitochondria as crucial players in demyelinated axons: lessons from neuropathology and experimental demyelination","volume":"2011","author":"Campbell","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.neurol.2026.03.009_bib0390","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/brain\/awn080","article-title":"Remyelination protects axons from demyelination-associated axon degeneration","volume":"131","author":"Irvine","year":"2008","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0395","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/bpa.12930","article-title":"Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis","volume":"31","author":"Sekyi","year":"2021","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0400","doi-asserted-by":"crossref","first-page":"27074","DOI":"10.1073\/pnas.1906358116","article-title":"Evoked potentials as a biomarker of remyelination","volume":"116","author":"Heidari","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.03.009_bib0405","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1093\/brain\/awac207","article-title":"Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy","volume":"145","author":"Cordano","year":"2022","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0410","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0415","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2026.03.009_bib0420","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2026.03.009_bib0425","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0430","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/13524585241233177","article-title":"Bexarotene leads to durable improvements in visual evoked potential latency: a follow-up study of the Cambridge Centre for Myelin Repair One trial","volume":"30","author":"McMurran","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0435","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s13063-025-09254-2","volume":"26","author":"Riboni-Verri","year":"2025","journal-title":"Trials"},{"key":"10.1016\/j.neurol.2026.03.009_bib0440","doi-asserted-by":"crossref","first-page":"e076651","DOI":"10.1136\/bmjopen-2023-076651","article-title":"Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE)","volume":"14","author":"Hof","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2026.03.009_bib0445","doi-asserted-by":"crossref","first-page":"102015","DOI":"10.1016\/j.msard.2020.102015","article-title":"randomized trial of liothyronine for remyelination in multiple sclerosis: a dose-ranging study with assessment of reliability of visual outcomes","volume":"41","author":"Wooliscroft","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.03.009_bib0450","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0455","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1352458517742979","article-title":"Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial","volume":"25","author":"McKee","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0460","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0465","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1474-4422(21)00322-7","article-title":"Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study","volume":"20","author":"Lagr\u00e8ze","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0470","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0475","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(25)01039-6","article-title":"Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Chataway","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.03.009_bib0480","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.03.009_bib0485","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-018-0528-2","article-title":"MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study","volume":"32","author":"Tourbah","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2026.03.009_bib0490","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.03.009_bib0495","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1352458520964409","article-title":"Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Bermel","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0500","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/WNL.0000000000207551","article-title":"Effects of ibudilast on retinal atrophy in progressive multiple sclerosis subtypes: post hoc analyses of the SPRINT-MS Trial","volume":"101","author":"Ehrhardt","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0505","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(25)00304-7","article-title":"2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0510","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0515","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/WNO.0000000000001870","article-title":"Predictors of long-term visual acuity in a modern cohort of patients with acute idiopathic and multiple sclerosis-associated optic neuritis","volume":"43","author":"Jarocki","year":"2023","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0520","doi-asserted-by":"crossref","first-page":"e1135","DOI":"10.1212\/NXI.0000000000001135","article-title":"Optic nerve lesion length at the acute phase of optic neuritis is predictive of retinal neuronal loss","volume":"9","author":"Denis","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2026.03.009_bib0525","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2011.243","article-title":"Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes","volume":"69","author":"Naismith","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0530","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10633-010-9216-3","article-title":"Repeatability of short-duration transient visual evoked potentials in normal subjects","volume":"120","author":"Tello","year":"2010","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0535","doi-asserted-by":"crossref","first-page":"115565","DOI":"10.1016\/j.expneurol.2025.115565","article-title":"Tracking remyelination in a model of multiple sclerosis: visual evoked potentials reveal therapeutic effect from brain stimulation and exercise","volume":"397","author":"Rossi","year":"2026","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0540","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10633-014-9467-5","article-title":"Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes","volume":"130","author":"Narayanan","year":"2015","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0545","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","article-title":"The APOSTEL recommendations for reporting quantitative optical coherence tomography studies","volume":"86","author":"Cruz-Herranz","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0550","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1352458514538110","article-title":"Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria","volume":"21","author":"Schippling","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0555","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20851","article-title":"Quantifying axonal loss after optic neuritis with optical coherence tomography","volume":"59","author":"Costello","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0560","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ana.20575","article-title":"Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis","volume":"58","author":"Trip","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0565","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0570","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.24351","article-title":"Dynamics of retinal injury after acute optic neuritis","volume":"77","author":"Gabilondo","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0575","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/1352458511418630","article-title":"Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness","volume":"17","author":"Saidha","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0580","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00415-016-8127-y","article-title":"Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study","volume":"263","author":"Balk","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0585","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1212\/01.WNL.0000094315.19931.90","article-title":"Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite","volume":"61","author":"Balcer","year":"2003","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"10.1016\/j.neurol.2026.03.009_bib0590","first-page":"S16","article-title":"Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity","volume":"74","author":"Balcer","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.03.009_bib0595","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0600","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/13524585251396433","article-title":"Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): a randomized, controlled, phase 2 trial","volume":"32","author":"Calabresi","year":"2026","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.03.009_bib0605","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/brain\/awu335","article-title":"Vision and vision-related outcome measures in multiple sclerosis","volume":"138","author":"Balcer","year":"2015","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2026.03.009_bib0610","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:14:41Z","timestamp":1792674881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726005023"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.03.009","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remyelination and neuroprotection translational trials: Lessons from optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}